BioWorld Asia

April 4, 2007

Gene Therapy Gains Boost With $690M Collaboration

LONDON - Big pharma has publicly embraced gene therapy for the first time, with the signing of a $690 million deal between Sanofi-Aventis SA and Oxford BioMedica plc for TroVax. (BioWorld International) Read More

CardioVascular Seeks AIM Status To Negate Naked Short Selling

New Enzyme Technology Could Solve Blood Supply Problems

Evotec Acquires Neuro3d Cash, Assets For $29.4M In Stock

EU Creating Registry To Boost Coordination Of Stem Cell Work

Advanced Therapies Rule Hits New EU Problems

MilleGen and LFB Partner On New Generation of MAbs

Pfizer Initiates Development Of NicOx Glaucoma Drug Candidate

Other News To Note

Nitec Pharma Gets $26M For Lodotra Development

Affibody Issues $28.5M In Shares To Boost New Diagnostic Tool

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2026.

Depression concept with human, broken brain and heavy rain

CROI 2026 highlights depression and cognitive vulnerability in HIV

BioWorld

The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

University of Southern California reports new MAPT aggregation inhibitors

BioWorld Science

The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein...

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...